Foresite Capital Management VI’s Akero Therapeutics AKRO Stock Holding History

Foresite Capital Management VI’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-244,900	Closed	-$11.6M	–	13
2025 Q3	$11.6M	Hold	244,900	–	–	4.49%	8
2025 Q2	$13.1M	Sell	244,900 -120,100	-33%	-$5.46M	7.35%	3
2025 Q1	$14.8M	Hold	365,000	–	–	8.09%	5
2024 Q4	$10.2M	Buy	+365,000	New	+$11.1M	4.52%	8

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Foresite Capital Management VI's AKRO Position: Q4 2025 in Review

Foresite Capital Management VI sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 244,900 shares — an estimated $11.6M sold.

Foresite Capital Management VI first reported a position in AKRO in Q4 2024 and held it in 4 quarters. The position peaked at $14.8M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Foresite Capital Management VI reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Foresite Capital Management VI sold 244,900 Akero Therapeutics shares in Q4 2025, an estimated $11.6M.
Foresite Capital Management VI first reported a position in Akero Therapeutics in Q4 2024 and held it in 4 quarters.
Foresite Capital Management VI's Akero Therapeutics position peaked at $14.8M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Foresite Capital Management VI's 13F filing for Q4 2025, filed 17 Feb 2026.